Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Mixed-size DNA fragments in a blood sample may predict residual cancer as well as MRI scans.
A personalized blood test can detect colon cancer recurrence sooner than scans.
An inside look at five research developments that have the potential to transform the treatment of cancer
Tests for circulating tumor DNA can help predict which patients are more likely to relapse.
The blood test identifies biomarkers that could make patients eligible for targeted therapies.
The FoundationOne CDx test identifies solid tumors with NTRK fusions.
Guardant360 identifies patients with EGFR mutations, which could guide treatment decisions.
New research from UCSF and City of Hope examines limitations in coverage for liquid biopsy genomic testing in cancer care.
A novel liquid biopsy method can detect kidney cancers with high accuracy, including small, localized tumors which are often curable.
Many people with GI cancers are diagnosed only after the disease has spread through the body, so this test could aid in early detection.
A study looked at circulating tumor DNA as a biomarker for health outcomes among women with triple-negative breast cancer.
In study, test proved able to detect and localize more than 20 types of cancer with a high degree of accuracy.
The test was able to identify many cancers, and their location, at early stages.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.